View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up

View from the Thoraxcenter: AHA 23 Wrap Up

Average (ratings)

No ratings

•

Your rating

What's hot at #AHA23? Listen to the podcast version of the popular review series.

Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.

They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.

Trials Covered include:
00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack

06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial

12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial

16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.

Read MoreRead Less

Audio Video

Episodes

Up Next

VHPSD versus Conventional Catheter Ablation in AF

Very-High Power Short Duration Vs Conventional Ablation for PVI in AF

EP30 • Dec 14, 2023 • 29m 53s

In this episode of the Radcliffe Podcast, we are joined by Dr Raymond Pranata, Dr Mohammad Iqbal and Dr Giky Karwiky (Hasan Sadikin General Hospital, Bandung, Indonesia) as they discuss their recently published systematic review and meta-analysis of very-high-power short-duration ablation as compared to conventional ablation for the treatment of pulmonary vein isolation in atrial fibrillation.

All Episodes

Ep 3: Atrial Fibrillation in Congenital Heart Disease

EP3 • Nov 30, 2021 • 16m 52s

Did you know that atrial arrhythmias are the most common complication in adults with congenital heart disease?

Dr Irene Martin de Miguel (Hospital General Universitario Gregorio Marañón, Madrid, Spain) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr de Miguel provides an overview of the current knowledge of AF in CHD, giving practical recommendations for your everyday practice.

Ep 2: Prognostication of patients with coronary stenoses: pre-and post-PCI

EP02 • Oct 29, 2021 • 20m 38s

Is there enough evidence to support the prognostic value of coronary physiology measurements in pre-and post-PCI settings? Is post-PCI FFR ready for clinical practice?

Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.

Ep 1: Women and Heart Disease

EP1 • Oct 01, 2021 • 44m 44s

Did you know that CV disease is the leading cause of death in women and that women are more likely to die of heart disease compared to men? Dr Erin Michos (John Hopkins Uni, US) and Dr Martha Gulati (Uni of Arizona, US) join us on the inaugural episode of the ECR podcast series to discuss issues surrounding women in heart disease. Together they explore a variety of topics that are addressed in the latest special focus issue in the European cardiology Review journal.

1 2 3 4

Targeting Inflammation in Atherosclerosis: Inflammation and Atherosclerosis

EP13 • May 13, 2022 • 8m 39s

Inflammation and Atherosclerosis – What is the Link with CKD? Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Lina Badimon (Hospital of Santa Creu and San Pau, Barcelona, Spain) as they discuss that very question.

Targeting Inflammation in Atherosclerosis: Therapeutic Targets and Mode of Action

EP12 • May 16, 2022 • 6m 42s

Prof Juan Carlos Kaski (St George’s University of London, UK) alongside Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) provide us with a short and concise discussion regarding Therapeutic Targets and Mode of Action.

Targeting Inflammation in Atherosclerosis: Inflammatory Signalling in Atherosclerosis and CKD

EP11 • May 13, 2022 • 8m 36s

Inflammatory Signalling in Atherosclerosis and CKD is the topic of interest in this short peer to peer discussion involving Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US).

Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Targeting Inflammation in Atherosclerosis: Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease

EP10 • May 13, 2022 • 9m 50s

Prof Juan Carlos Kaski (St George’s University of London, UK) is joined by Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) to discuss Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease where they cover topics such as elevated hsCRP and chronic kidney disease.

Targeting Inflammation in Atherosclerosis: COLCOT Trial

EP9 • Apr 22, 2022 • 5m 13s

Prof Jean-Claude Tardif (Montreal Heart Institute, Canada) gives us a comprehensive overview of the COLCOT trial.

... 2 3 4 5 6 7